SequelSEC

BIOREGENX, INC. BRGX

Services-Computer Programming, Data Processing, Etc. · CIK 0001593184 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$426.18K
Fiscal year ended 2026-03-31
Operating income
-$49.76K
Fiscal year ended 2026-03-31
Free cash flow
Unavailable
Fiscal year ended 2026-03-31

BIOREGENX, INC. (BRGX) reported revenue of $426.18K and net income of -$26.42K for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIOREGENX, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Computer Programming, Data Processing, Etc..

Income

BIOREGENX, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Revenue$426.18K$385.64K$507.76K$445.97K$515.15K$460.49K$596.04K$734.03K$549.55K$678.01K
Cost of revenue$77.89K$66.87K$81.36K$93.51K$109.12K$137.75K$114.39K$264.15K$165.39K$299.98K
Gross profit$348.29K$318.78K$426.40K$352.46K$406.03K$322.74K$481.65K$469.88K$384.16K$378.02K
Operating income-$49.76K-$935.66K-$8.46K-$107.26K-$192.62K-$18.32M-$327.31K-$1.04M-$3.08M-$211.56K
Net income-$26.42K-$1.02M-$80.56K-$178.34K-$266.85K-$18.40M-$394.86K-$1.11M-$3.15M-$256.75K
Research & developmentUnavailable$31.75K$0$0$0-$14.54K$0$7.50K$25.54K$82.65K
Weighted-average diluted sharesshares 969.17MUnavailableshares 960.87Mshares 959.21Mshares 956.99MUnavailableshares 956.53Mshares 956.53Mshares 767.60MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$704.81K-$719.97K
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0
Diluted EPS$0.00Unavailable$0.00$0.00$0.00Unavailable$0.00$0.00$0.00Unavailable
Selling, general & administrative$396.39K$552.09K$432.54K$456.73K$590.37K$1.87M$236.28K$1.40M$3.41M$494.52K
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIOREGENX, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailable$83.62K$58.40K$70.08K$57.40K$114.16K$125.40K
Total assets$337.07K$410.99K$1.17M$1.15M$482.62K$508.54K$17.36M$17.89M$18.62M$865.75K
Current assets$190.29K$251.26K$273.16K$249.57K$294.26K$307.80K$371.04K$326.08K$485.46K$652.66K
Total liabilities$4.87M$4.95M$4.81M$4.81M$4.04M$3.89M$3.80M$3.67M$3.53M$2.94M
Current liabilities$3.99M$4.07M$3.93M$3.93M$3.78M$3.63M$3.52M$3.42M$3.38M$2.79M
Total equity incl. NCI-$4.53M-$4.54M-$3.65M-$3.65M-$3.56M-$3.38M$13.56M$14.22M$15.09M-$2.07M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$92.81K$106.93K$109.38K$134.23K$140.44K$111.09K$158.73K$143.92K$213.34K$217.53K
Accounts receivable$18.38K$39.72K$62.61K$21.12K$11.16K$14.99K$19.44K$10.94K$11.18K$104.58K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$7.11M$7.11M$7.11M$0
Long-term debtUnavailable$181.82KUnavailableUnavailableUnavailable$254.61KUnavailableUnavailable$550.00K$0
Accounts payable$698.97K$615.99K$459.65K$568.80K$490.80K$427.48K$492.71K$431.81K$370.86K$241.70K

Cash flow

BIOREGENX, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Operating cash flow$26.63K$69.64K-$71.56K$3.20K$37.70K-$11.36K-$31.20K-$177.34K-$104.25K-$245.63K
Capital expendituresUnavailable$3.06K$6.00K$0$0$0$0$0$189.39K$0
Investing cash flowUnavailable-$3.06K-$6.00K-$50.00K$0$2.65K$0$0-$190.60K-$199.36K
Financing cash flow-$50.21K-$44.14K$70.83K$16.82K-$10.42K-$6.94K$46.44K$120.06K$282.56K$513.37K
Net change in cash-$23.58K$22.44K$491-$37.17K$25.22K-$11.68K$12.69K-$56.76K-$11.24K$67.44K
Stock-based compensation$6.78K$0$0$0$0$1.36M-$331.30K$172.85K$1.65M$2.24M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$12.94KUnavailable$12.38K$37.38K$12.38K$2.20M$12.38K$7.64K$500.53K$1.19K

Derived

BIOREGENX, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Free cash flowUnavailable$66.58K-$77.56K$3.20KUnavailable-$11.36K-$31.20K-$177.34K-$293.64K-$245.63K
Gross margin81.7%82.7%84.0%79.0%78.8%70.1%80.8%64.0%69.9%55.8%
Operating margin-11.7%-242.6%-1.7%-24.1%-37.4%-3977.7%-54.9%-141.7%-560.4%-31.2%
FCF marginUnavailable17.3%-15.3%0.7%Unavailable-2.5%-5.2%-24.2%-53.4%-36.2%
SBC / revenue1.6%0.0%0.0%0.0%0.0%295.2%-55.6%23.5%300.3%330.2%
Current ratio0.05x0.06x0.07x0.06x0.08x0.08x0.11x0.10x0.14x0.23x
Revenue YoY growth-17.3%-16.3%-14.8%-39.2%-6.3%-32.1%-25.0%-15.0%-48.9%7506.1%
Net margin-6.2%-263.9%-15.9%-40.0%-51.8%-3995.9%-66.2%-150.7%-573.6%-37.9%
R&D / revenueUnavailable8.2%0.0%0.0%Unavailable-3.2%0.0%1.0%4.6%12.2%
CapEx / revenueUnavailable0.8%1.2%0.0%Unavailable0.0%0.0%0.0%34.5%0.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BRGX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-K/A · Filed 2025-04-16View SEC filing

Companies in the same industry

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-09-30

Difference 2591452 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-06-30

Difference 2428600 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-03-31

Difference 2258312 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2022-12-31

Difference 2326396 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.